Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564

Affiliation auteurs!!!! Error affiliation !!!!
TitrePembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564
Type de publicationJournal Article
Year of Publication2021
AuteursChoueiri T.K, Tomczak P., Park S.H, Venugopal B., Symeonides S., Hajek J., Ferguson T., Chang Y-H., Lee J.L, Haas N., Sawrycki P., Sarwar N., Gross-Goupil M., Thiery-Vuillemin A., Mahave M., Saretsky T.L, Zhang P., Willemann-Rogerio J., Quinn D.I, Powles T.B
JournalANNALS OF ONCOLOGY
Volume32
PaginationS679-S680
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2021.08.049